BRAF and skin disorder: Indeed, larger studies might demonstrate whether B-RAF/MEK combo therapy can (i) both delay and prevent onset of resistance to therapy; (ii) significantly reduce the incidence of SCC formation fevers, chills, and MEK inhibitor-induced dermatitis; (iii) extend overall survival or if ipilimumab shall be implemented to confer a survival benefit in case of treatment failures (e.g., disease progression, unacceptable adverse events); (iv) recover patients that initially failed with monotherapy or provide potential benefit to initial monotherapy in order to further improve PFS.